Junliang Li

Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial

Weijie Gu, Weiqing Han, Hong Luo et al. · The Lancet Oncology · 2022 · 61 citations

Hormone-sensitive Prostate Cancer, Androgen-deprivation Therapy, Urology +9

High FN1 expression correlates with gastric cancer progression

Junliang Li, Cheng Chen, Bo Chen et al. · Pathology - Research and Practice · 2022 · 49 citations

Gastrointestinal Oncology, Pathology, Gastric Cancer Progression +3

UHRF1 overexpression is involved in cell proliferation and biochemical recurrence in prostate cancer after radical prostatectomy

Xuechao Wan, Shu Yang, Wenhua Huang et al. · Journal of Experimental & Clinical Cancer Research · 2016 · 40 citations · Full text

The CXCL12/CXCR4 axis confers temozolomide resistance to human glioblastoma cells via up-regulation of FOXM1

Shengwen Wang, Cheng Chen, Junliang Li et al. · Journal of the Neurological Sciences · 2020 · 32 citations

Neuro-oncology, Cell Regulation, Glioma +11

Dual role of cadmium in rat liver: Inducing liver injury and inhibiting the progression of early liver cancer

Honglong Zhang, Jun Yan, Ye Xie et al. · Toxicology Letters · 2021 · 30 citations

Early Liver Cancer, Hepatology, Dual Role +13